Personal Finance

Up 188.7%, Is bluebird bio. Stock Still a Strong Buy?

Human cancer cell.

What happened

Shares of the clinical-stage gene-therapy company bluebird bio. (NASDAQ: BLUE) gained a stately 188.7% in 2017, according to data from S&P Global Market Intelligence . The market's glowing enthusiasm for the biotech was sparked by the unprecedented clinical trial results for its chimeric antigen receptor T-cell (CAR-T) candidate bb2121 in patients with relapsed/refractory multiple myeloma. The cell-based therapy is being co-developed with Celgene Corp. (NASDAQ: CELG) .

Human cancer cell.

Image source: Getty Images.

So what

At the American Society of Hematology Annual Meeting last December, bluebird and Celgene provided an extremely encouraging clinical update on bb2121's ongoing dose-escalation study. The two companies reported that 17 out of 18 patients exhibited an objective response when treated with bb2121, far outpacing the response rates for other FDA-approved treatments for advanced multiple myeloma. In other words, bluebird and Celgene appear to have a big winner on their hands with this experimental cell-based cancer therapy.

Now what

At this year's J.P. Morgan Healthcare Conference, bluebird bio.'s management said they are hoping to have bb2121 under regulatory review in both the United States and Europe by 2019. Meanwhile, the company is planning on filing for approval for its transfusion-dependent beta thalassemia candidate LentiGlobin in Europe later this year. And last but not least, bluebird is aiming to have its cerebral adrenoleukodystrophy candidate Lenti-D under review by 2019, as well.

So, this developmental-stage biotech definitely has a number of major catalysts on the calendar to keep investors' interest moving forward. And with over a billion in cash and investments in its coffers, bluebird certainly has the financial resources necessary to make good on this aggressive regulatory timeline. As such, investors shouldn't be surprised if bluebird continues to outperform the broader markets in 2018.

10 stocks we like better than Bluebird Bio

When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has tripled the market.*

David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and Bluebird Bio wasn't one of them! That's right -- they think these 10 stocks are even better buys.

Click here to learn about these picks!

*Stock Advisor returns as of January 2, 2018

George Budwell has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends Bluebird Bio and Celgene. The Motley Fool has a disclosure policy .

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story


Other Topics


The Motley Fool

Founded in 1993 in Alexandria, VA., by brothers David and Tom Gardner, The Motley Fool is a multimedia financial-services company dedicated to building the world's greatest investment community. Reaching millions of people each month through its website, books, newspaper column, radio show, television appearances, and subscription newsletter services, The Motley Fool champions shareholder values and advocates tirelessly for the individual investor. The company's name was taken from Shakespeare, whose wise fools both instructed and amused, and could speak the truth to the king -- without getting their heads lopped off.

Learn More